Nanosuspension Formulation Research Articles

Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease.

Loteprednol etabonate is a soft corticosteroid that is rapidly deactivated after reaching the general circulation, displaying good local activity and a high therapeutic index without inducing systemic side effects. In 2021, Kala Pharmaceuticals launched Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% in the U.S. for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. Approval by the Food and Drug Administration (FDA) was based on results from one phase II trial and three phase III trials showing Eysuvis significantly improved both the signs and symptoms of dry eye disease and was well tolerated. Eysuvis is a novel loteprednol etabonate nanosuspension formulation developed by Kala using its AMPPLIFY mucus-penetrating particle (MPP) drug delivery technology. Use of this MPP formulation results in enhanced penetration of loteprednol etabonate into target tissue on the ocular surface. Eysuvis is the first FDA-approved ocular corticosteroid indicated for dry eye disease.

Assessment of Pharmacokinetic Parameters of Daidzein-Containing Nanosuspension and Nanoemulsion Formulations After Oral Administration to Rats

Daidzein has several biological effects such as antioxidation, anti-inflammation, chemoprevention, and anticancer effects.The aim of this study was to evaluate the impact of nano-formulations (nanoemulsion-NE and nanosuspension-NS) prepared to increase the oral bioavailability of daidzein, a poorly water-soluble isoflavone, on the pharmacokinetic parameters of daidzein in rats. A high-performance liquid chromatography-ultraviolet (HPLC-UV) method was successfully developed for daidzein analysis in rat plasma.The pharmacokinetics studies of the nano-sized formulations, compared to coarse daidzein suspension, were carried out in the rats by a single oral dose at 10 mg/kg (n=6/group). Area under the plasma concentration-time curve from time zero to extrapolation to time infinity (AUC0-∞), maximum plasma concentration (Cmax), time to reach maximum plasma concentration (tmax), andelimination half life (t1/2)values for coarse daidzein suspension, daidzein-NS, and daidzein-NE were estimated by a non-compartmental analysis. The AUC values of daidzein-NE and daidzein-NS were approximately 2.62 and 2.65 times higher than that of coarse daidzein suspension, respectively (p<0.05). Relative bioavailability (Frel) (%) values of daidzein following oral administration of nanosuspension or nanoemulsion formulations were about 265.6% and 262.3%, respectively. It revealed that nanoscale size is an important factor to overcome any dissolution rate barriers to oral bioavailability of the low water-soluble compound. Nanoemulsion and nanosuspension formulations are beneficial dosage forms to increase the oral bioavailability of Biopharmaceutical Classification System (BCS) Class II and Class IV compounds.

Formulation, Evaluation, and Optimization of Glimepiride Nanosuspension by Using Antisolvent Evaporation Technique

Recent work aimed to prepare nanosuspension of glimepiride by using antisolvent evaporation followed by sonication technique. As glimepiride belongs to BCS class II, thus it has less solubility and high permeability. Hence to enhance the solubility of glimepiride, it was formulated into nanosuspension. Different polymers were used to prepare stable nanosuspension by taking several trial batches. After getting the results from trial batches, the combination of Pluronic F68 and PEG 400 was selecte

Enhancing pharmaceutical potential and oral bioavailability of Allium cepa nanosuspension in male albino rats using response surface methodology

Objective: To enhance the pharmaceutical potential and oral bioavailability of quercetin contents of Allium cepa peel extract by novel nanosuspension technology. Methods: Nanoprecipitation approach was successfully used for the formulation of nanosuspension. To obtain pharmaceutical-grade nanosuspension with minimum particle size and polydispersity index, sodium lauryl sulphate was selected as a stabilizer. Important formulation parameters were statistically optimized by the response surface methodology approach. The optimized nanosuspension was subjected to stability and in vitro dissolution testing and characterized by scanning electron microscopy, atomic force microscopy, Fourier transform infrared spectroscopy, and zeta sizer. To evaluate the preeminence of nanosuspension over coarse suspension, comparative bioavailability studies were carried out in male albino rats. The pharmaceutical potential of developed nanosuspension was evaluated by antioxidant, antimicrobial, and toxicity studies. Results: The optimized nanosuspension showed an average particle size of 275.5 nm with a polydispersity index and zeta potential value of 0.415 and -48.8 mV, respectively. Atomic force microscopy revealed that the average particle size of nanosuspension was below 100 nm. The formulated nanosuspension showed better stability under refrigerated conditions. Nanosuspension showed an improved dissolution rate and a 2.14-fold greater plasma concentration of quercetin than coarse suspension. Moreover, the formulated nanosuspension exhibited enhanced antioxidant and antimicrobial potential and was non-toxic. Conclusions: Optimization of nanosuspension effectively improves the pharmaceutical potential and oral bioavailability of Allium cepa extract.

Optimization of Formulation and Operating Parameters for Ginkgo biloba Extract Nanosuspension by Wet Ball Milling Using a Box–Behnken Design

In the present work, the formulation of nanosuspension of Ginkgo biloba extract (GBE) and the operating parameters of wet ball milling (WBM) was optimized using the Box–Behnken design (BBD) method. The key formulation factors evaluated were GBE concentration, milling speed, milling time, and sodium dodecyl sulfate (SDS) concentration. A quadratic model with the correlation coefficient ( R 2 ) value of 0.9276 was established based on the experimental data, implying that this model is significant; meanwhile, the analysis of variance (ANOVA) showed that the SDS concentration was the most significant factor on particle size, followed by GBE concentration, milling speed, and milling time was the slighter significant factor. The GBE nanosuspension with the particles size of 171.2 nm was prepared under the optimized conditions of GBE concentration (7.459 g/L) in combination with milling time (1.492 h), milling speed (9.253 m/s), and SDS concentration (0.846 g/L). The freeze-dried nanosuspension exhibited spherical particle morphology with uniform size by scanning electron microscopy. In addition, the melting behavior of the raw material and milled GBE was analyzed by differential scanning calorimetry and it was found that the melting point decreased due to the decrease of particle size. Furthermore, the dissolution rates of the optimized GBE showed better dissolution properties than the unprocessed GBE. The results show that it is feasible to prepare GBE nanosuspension on a commercial scale by WBM to increase the bioavailability of GBE.

Nanosuspension of Poorly Soluble Anti-Diabetic Drug for Enhancement of Solubility and Dissolution

Canagliflozin is an anti-diabetic drug used in the adjuvant therapy for type-II diabetes as the inhibitor of sodium‐glucose co‐transporter-2 in the renal tubules. The poor solubility and permeability of the drug show limitations in the formulation development and therapeutic plasma concentration. The objective of the work was to improve the solubility and dissolution of the BCS class IV drug through surfactant stabilized nanosuspension formulation. Nanoparticles were developed by Nano precipitation-solvent evaporation method using Poly vinyl alcohol and Pluronic as surfactants at 1%, 3% and 5% concentration. Formulation optimized with Pluronic exhibited nano size particles (81-117 nm) with monodisperse nature and high stability zeta potential. The nanosuspension prepared using 1% and 3% Pluronic F127 showed 2-fold and 5- fold increase in the drug dissolution compared to the pure drug aqueous dispersion. The drug and surfactant exhibited mild interactions due to hydrogen bonding and hydrophobic interactions as confirmed by the FTIR and TG-DSC analysis, which favoured the formation of stable nanoparticles. The SEM proved the formation of smooth surface spherical shaped nanoparticles. Hence, the development of Canagliflozin nano-formulation was evidenced be an optimized approach to enhance the dissolution of the drug.

Evaluating of Two Type of Cyclosporine-A Containing Nanosuspension for Ophthalmic Administration

Dry eye is both a common symptom and a disease. It is known that the ophthalmic emulsion of the immunomodulator cyclosporine-A (Cyc-A) has a positive effect on this condition but its’ absorption to intraocular tissues is limited. Nanosuspension is a drug formulation that aims to increase the bioavailability. The aim of this study was to develop a Cyc-A nanosuspension formulation for a better intraocular absorption via ocular delivery and to investigate the effectiveness of the formulation by comparing it with two marketed ophthalmic emulsions (Restasis® and Depores®). Two type of Cyc-A loaded Eudragit S100 nanosuspension (A and B) were prepared. Drug formulations were applied to both eyes of 20 male Albino New Zealand rabbits with an interval of 12 hours for 14 days. In vitro drug release was tested using a dialysis sac and quantitative analysis was performed by HPLC for evaluating Cyc-A amounts in all formulations. Although all four formulations had similar particle size and polydispersity indexes, nanosuspension B which had a positive zeta potential value, had released more Cyc-A than other formulations. It was showed that Cyc-A loaded nanosuspension formulations which had good ocular tolerability could be a better alternative to commercial formulations for the treatment of dry eye. The nanosuspensions have ideal mean particle size range with a positive surface charge for ophthalmic applications of Cyc-A.

Formulation and Evaluation of Lamivudine Nanosuspension

The present research aimed to develop &amp; Evaluation of Lamivudine Nanosuspension. Lamivudine is a potent in vitro inhibitor of human immune deficiency virus belongs to the category of anti-retroviral drugs. The formulated Nanosuspension was subjected to various evaluation parameters like particle size, polydispersity index, zeta potential, drug content, viscosity, saturation solubility studies, In vitro release, treatment of kinetic data, and stability studies. The polydispersity ranged from 0.218 PDI to 0.331 PDI and zeta potential ranged from -1.60 mV to -4.79 mV are the important evaluation parameters are responsible for the stability of nanosuspensions. The Polydispersity index presents the quantity of particle size distribution ranges from 452.4 nm to 532.2 nm. In this result, LNSF4 shows spectacular drug content range of 86±1.8% to 97±2.5% it is the maximum drug content. The Brook field viscometer to determine the viscosity of Lamivudine Nano suspension of different formulations was found to be 44.4±2.1 cps to 87.7±1.4 cps. The general Nanosuspension formulations LNSF4 shows 98.64 % better controlled released in comparison with abundant formulation. In all the cases the best-fit model encounter uoto be peppas with ‘n’ value between 0.768 to 0.917. The ‘n’ value of formulation LNSF4 was 0.876 and suggesting so the drug was released by Zero-order kinetics. Acceleration stability studies intermediate storage condition has been changed from 30°C ± 2°C and 60% RH ± 5% Relative Humidity. After a 90 days study it revolves that there’s no change in Drug content, In vitro drug release, and particle size.&#x0D; Keywords: Lamivudine, Nanosuspension, Saturation solubility, Scanning Electron Microscopy, Stability study.

Formulation and Evaluation of Benidipine Nanosuspension

In the interest of administration of dosage form oral route is most desirable and preferred method. After oral administration to get maximum therapeutic effect, major challenge is their water solubility. Water insoluble drug indicate insufficient bioavailability as well dissolution resulting in fluctuating plasma level. Benidipine (BND) is poorly water soluble antihypertensive drug has lower bioavailability. To improve bioavailability of Benidipine HCL, BND nanosuspension was formulated using media milling technique. HPMC E5 was used to stabilize nanosuspension. The effect of different important process parameters e.g. selection of polymer concentration X1(1.25 mg), stirring time X2 (800 rpm), selection of zirconium beads size X3 (0.4mm) were investigated by 23 factorial design to accomplish desired particle size and saturation solubility. The optimized batch had 408 nm particle size Y1, and showed in-vitro dissolution Y2 95±0.26 % in 30 mins and Zeta potential was -19.6. Differential scanning calorimetry (DSC) and FT-IR analysis was done to confirm there was no interaction between drug and polymer.

Redispersible nanosuspensions as a plausible oral delivery system for curcumin

Curcumin is widely used as a nutraceutical ingredient in food and beverage products. It has been reported that curcumin has a broad spectrum of biological activities such as anticancer, anti-inflammatory, antioxidant, and antibacterial effects. Despite the potent therapeutic effect of curcumin, its low aqueous solubility, stability, and oral bioavailability limits its effectiveness. In order to improve the physical and chemical properties of curcumin, we have formulated curcumin as a nanosuspension by using the emulsion templated freeze-drying technique. This approach produces a solid that can be dispersed as required to form a nanosuspension. The formulations were investigated in a screening process using various excipients, resulting in the identification of one curcumin nanosuspension sample which contained only polyethylene glycol (PEG) as the excipient. This formulation exhibited a small diameter (211 nm), low polydispersity (0.06) and zeta potential of −25 mV and was therefore chosen for further in vitro investigations. Various experimental parameters such as active agent and excipient concentrations, and sonication time were varied to tune the size and polydispersity of the chosen formulation. The resulting nanosuspension showed an improved chemical stability at pH values that mimic the gastrointestinal tract. An in vitro bioaccessibility experiment showed that the nanosuspension formulation resulted in more dissolution of the curcumin but this was also coupled with reduced stability. Cytotoxicity studies showed that the nanosuspension offered a reduced cytotoxicity profile compared to the solubilised curcumin on both cell lines investigated. This redispersible curcumin nanosuspension formulation may provide new opportunities for the oral dosing of curcumin.

Development of a Nanocrystal Formulation of a Low Melting Point API Following a Quality by Design Approach

Preparation of nanocrystal formulations by wet media milling and spray-drying is a reliable technique to enhance dissolution and ameliorate absorption limitations of poorly soluble BCS II drugs. However, when thermosensitive compositions are dried at high temperatures, the risks of particle aggregation and thermal degradation must be considered. The present study investigates the effects of nanosuspension formulation variables when performing the spray drying process at equidistant temperatures above and below the melting point. Towards this purpose, Fenofibrate is exploited as a model drug of unfavorable pharmacokinetic profile and low melting point (79–82 °C), properties that render thermal processing a nontrivial task. Rationalizing the system’s behavior by combining molecular simulations with QbD methodology, the preparation of stable nanocrystals can be “steered” in order to avoid undesirable melting. The statistically resolved operational conditions showed that Fenofibrate Critical Quality Attribute–compliant nanosuspensions i.e., bearing hydrodynamic diameter and ζ-potential of 887 nm and −16.49 mV, respectively, were obtained by wet milling drug to Pharmacoat and mannitol weighted optimum ratios of 4.075% and 0.75%, after spray drying at the desired temperature of 77 °C. In conclusion, we present a quality assurance methodology of nano-comminution generally applicable for thermo-labile BCS II drugs.

Formulation and Evaluation of Benidipine Nano-suspension by Precipitation Method using Central Composite Design

In the interest of administration of dosage form oral route is most desirable and preferred method. Poor solubility and slow dissolution rate major challenges in upcoming and existing therapeutically active compound. Water insoluble drug indicate insufficient bioavailability as well dissolution resulting in fluctuating plasma level. Benidipine (BND) is Biopharmaceutical Classification System Class-II drug having low solubility and high permeability, antihypertensive drug has lower bioavailability. The purpose of the present study was to improve solubility as well dissolution profile of Benidipine HCL. BND nanosuspension was formulated using precipitation technique. Various polymers were evaluated viz. HPMC E15, Tween 20, PVP K30 in preliminary trial to stabilized nanosuspension but PVP K30 was selected among them. The solubility of BND was carried out using different solvents like Ethanol, Acetonitrile; Acetone. Ethanol was used as a preferred solvent as BND shows high solubility in it. The effect of different important process parameters e.g. selection of polymer concentration X1(10 mg), solvent concentration X2 (0.2 ml) were investigated by Central Composite factorial design to accomplish desired particle size and rate of dissolution. Stirring speed and time of stirring was kept constant as 1000 rpm and 2h respectively. To achieve optimized batch, 9 formulations (F1-F9) were prepared. The optimized batch had 237 nm particle size Y1, and showed in-vitro dissolution Y2 98±0.72 % in 30 mins related to pure BND (58±0.25%) and zeta potential was -15.3. None of interaction between drug and polymer was confirmed by Differential scanning calorimetry (DSC) and FT-IR analysis. The obtained results showed that issues related particle size (nm) and rate of dissolution of BND has been solved when nanosuspension can be prepared by precipitation method by considering optimized parameter due to formation of nanosized particles

Development, Characterization and Comparative Phar-macokinetic Evaluation of Ritonavir Nanosuspension, with a Model Nanoemulsion and Coarse Suspension for Improved Oral Delivery

Ritonavir (RV) is an antiretroviral drug, classified as BCS class II pharmaceutical active.It has limited bioavailability due to poor aqueous solubility and first pass metabolism. The purpose of this investigation was to develop optimal nanosuspension and to compare with a model nanoemulsion of RV for improved oral delivery. DSC studies showed good compatibility of excipients with drug. Nanosuspension was prepared by high pressure homogenization, while nanoemulsion was prepared by hot homogenization followed by ultrasonication. All prepared RV formulations were characterized and optimal system was selected and in vivo evaluated. Nanosuspension (F1) formulation containing 0.5% SLS showed homogeneity with least particle size was optimized and compared with coarse (powder) suspension. SEM studies on lyophilized nanosuspension revealed the absence of needle shaped drug crystals, indicating the loss of crystallinity. Prepared a model lipid nanoemulsion. It was having the size, PDI, ZP, EE and assay of 193.14 ± 12.66nm, 0.311 ± 0.04, -27.6 ± 1.184mV, 90.79 ± 0.319% and 99.57 ± 1.25% respectively. Next, a comparative pharmacokinetic study of RV nanosuspenison with respect to lipid nanoemulsion and coarse suspension was performed in male wistar rats. The Cmax of nanosuspension was significantly more when compared to that of NE or coarse drug suspension. The tmax was similar in case of both nanodelivery systems and significantly less when compared to that of coarse suspension. About 1.36 and 1.27 fold improvements in relative bioavailability (BA) of ritonavir via lipid nanoemulsion and nanosuspension were found when compared to coarse suspension. The study results revealed nominal but nonsignificant difference in oral bioavailability for the two nanodelivery systems. Taken together, this study confirmed the potential of nanosuspension and nanoemulsion systems in improving the bioavailability of ritonavir.

Formulation and evaluation of nanosuspension loaded microbeads for enhancing oral bioavailability of BCS class IV drug

Formulation and evaluation of nanosuspension loaded microbeads for enhancing oral bioavailability of BCS class IV drug

Nanosuspension formulation &amp; evaluation of ritonavir &amp; valsartan by using poloxamer as a stabilizing agent to enhance the oral bio availability

The Nano ionization technology is particularly promising for improving the oral absorption and bioavailability of BCS class II drugs. One such approach is Nano ionization thereby increasing surface area and hence dissolution and ultimately the bioavailability. Ritonavir is a BCS class II and IV drug. Valsartan is a commonly used antihypertensive agent belonging to the family of angiotensin II receptor antagonists. Valsartan is a BCS class II drug being slightly soluble in water. It has a very low oral bioavailability of 25-35% due to its limited solubility in biological fluids. Poor water solubility of drugs shows insufficient bioavailability and fluctuating plasmalevels. Based on their physicochemical and biopharmaceutical properties, Ritonavir and Valsartan were selected as a drug candidates for developing Nanosuspension based formulations for improving the solubility and bioavailability by enhancing the rate and extent ofdissolution.The scope of the present work is to enhance the solubility, dissolution rate and oral bio availability of poorly soluble drugs Ritonavir and Valsartan by formulating them into Nanosuspension with Poloxamer as a stabilizing agent and subsequently converting the optimized Nanosuspension of Ritonavir/Valsartan drug molecule into tablets and capsuleswith the help of various extragranular agents.

Adaptive Focused Acoustics™ for Nanosuspensions to Enable Pharmacology Assessment of Poorly Soluble Molecules in Lead Optimization.

In Drug Discovery, pharmacology studies often require benign formulation compositions for safe administration in animal models. Here, we applied Adaptive Focused Acoustics™ (AFA) to a molecular scaffold with challenging physicochemical properties for intraperitoneal administration. Nanosuspensions can be prepared at small scales and provide broad applicability. Our results show that nanosuspension formulations prepared by AFA have improved PK performance relative to a DMSO solution formulation that is prone to precipitation in-vivo.

Formulation development and characterization of lumefantrine nanosuspension for enhanced antimalarial activity

Variable and low oral bioavailability (4-11%) of lumefantrine (LUF), an anti-malarial agent, is characterized by very low solubility in aqueous vehicle. Thus, the present study was intended to formulate lyophilized nanosuspensions of LUF to resolve its solubility issues for the improvement of oral bioavailability. A three level 32 factorial design was applied to analyze the influence of independent variables, concentration of polysorbate 80 (X1) and sonication time (X2) on the responses for dependent variables, particle size (Y1) and time to 90% release of LUF (t90) (Y2). Optimized formulation (F3) has shown to possess lowest particle size (95.34 nm) with minimum t90 value (⁓3 mins), which was lyophilized to obtain the dry powder form of the nanosuspension. The characterization parameters confirmed the amorphous form of LUF with good stability and no chemical interactions of the drug with the incorporated components. Further, saturation solubility study revealed increased solubility of the LUF nanosuspension (1670 µg/mL) when compared to the pure drug (212.33 µg/mL). Further, rate of dissolution of LUF from the nanosuspension formulations were found to be significantly (p < 0.05) higher when compared to the pure drug. Fabricated lyophilized nanosuspension was found to be stable at 25 ± 2 °C/60 ± 5% RH and 40 ± 2 °C/75 ± 5% RH for the duration of three months. In conclusion, lyophilized nanosuspension showed ∼8-folds increase in drug release, which indicated a better way to offer higher release of LUF in controlling malaria.

Formulation and optimization of gefitinib-loaded nanosuspension prepared using a newly developed dendritic lipopeptide oligomer material

Amino acid derived polypeptides are often biocompatible, and hence the materials of choice in nanoparticle formulations to avoid nanotoxicity and associated complications. A hydrophilic linear polypeptide γ-poly(l-glutamic acid) can form self-assembled nanoparticles only when made amphiphilic by chemical modification. Present work investigated pharmaceutical feasibility of a newly synthesized l-glutamic acid-based dendritic lipopeptide oligomer, which was found to be biocompatible and devoid of any inherent anticancer activity in vitro. Gefitinib, a poorly water-soluble anticancer drug, was used as the model drug to prepare an oligomeric nanosuspension by solvent evaporation–ultrasonication method. The formulation was optimized using response surface methodology and Box–Behnken model of design of experiments. The optimized gefitinib-loaded oligomeric nanosuspension demonstrated acceptable particle-size distribution, surface morphology, colloidal stability, entrapment efficiency, and drug release profile. Overall, current work highlights competence of a newly synthesized dendritic lipopeptide oligomer for drug delivery applications.

Formulation and characterization of gliclazide nanosuspension

The core objective of the present study was to formulate and characterize Gliclazide nanosuspension by using different polymers to improve the solubility and bioavailability of a drug. The formulation of Gliclazide Nanosuspension was done by the Nano precipitation method. The formulations were prepared by different polymers and surfactants. The formed nanosuspension was clear and no sedimentation on shaking. The Gliclazide formulation showed maximum solubility in HPMC. The preformulation parameters were evaluated like solubility, identification of sample by UV spectroscopy, FTIR studies. The viscosity of the dispersion medium was in F5 0.89m Pa-s, the zeta potential value was found to be-20.5mv. The SEM studies showed that the nanoparticles had a smooth surface. All the fabricated Gliclazide Nanosuspension were subjected to In vitro drug release, in this F5 which showed the highest % of drug release. The optimized formulation (F5) was compared with the marketed sample which has the same release pattern. The release kinetics confirmed that the optimized formulation followed zero-order kinetics. From this study, it has been concluded that the modified liquid dosage form complies the patient compliance and it is suitable for dose titration therapy in diabetes treatment.

Nanosuspensions by Solid Lipid Nanoparticles method for the Formulation and In vitro/in vivo, characterization of Nifedipine

Nifedipine is a dihydropyridine calcium channel antagonist initially prescribed for treatment of angina pectoris and hypertension. The drug belongs to BCS Class-2 drug, is poorly water soluble drug, it suffers from a poor aqueous solubility, hence the delays its onset of action. Therefore, the purpose of the research study is to adopt the nanotechnology to formulate nanoparticles that improve the rate of dissolution of drug and to get desired bioavailability of nifedipine. Nanosuspensions were prepared by Solid Lipid Nano Particles method in the presence of selected stabilizers at different concentrations. The nanosuspensions were determined for their particle size of drug, zeta potential of drug, drug content and drug dissolution. The selected formula was freeze dried and illustrated by scanning electron microscopy (SEM), FT-IR, differential scanning calorimetry (DSC), and pharmacokinetic study. The in vitro dissolution confirmed the rate of drug release greater compared to the pure drug. The optimum formula has a typical particle size of 225.56±4.65nm and zeta potential of -17.84±2.17 mV. The bioavailability parameters in the rabbits were enhanced by 2 folds when compared with the marketed tablets (Calcigard®). Solid lipid nanoparticles method was successfully employed to produce stable Nifedipine nanosuspension by using the suitable concentration of stabilizer (PVA, Tween 80, PVP and HPMC). From this study, it is concluded that formulation of Nifedipine nanosuspension may be a competent approach that boost the rate of dissolution and hence oral bioavailability of drug.